This Article  • Abstract  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (448)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Review  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review

Barry J. Maron, MD

JAMA. 2002;287:1308-1320.

ABSTRACT
Context  Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a broad and expanding clinical spectrum.

Objectives  To clarify and summarize the relevant clinical issues and to profile rapidly evolving concepts regarding HCM.

Data Sources  Systematic analysis of the relevant HCM literature, accessed through MEDLINE (1966-2000), bibliographies, and interactions with investigators.

Study Selection and Data Extraction  Diverse information was assimilated into a rigorous and objective contemporary description of HCM, affording greatest weight to prospective, controlled, and evidence-based studies.

Data Synthesis  Hypertrophic cardiomyopathy is a relatively common genetic cardiac disease (1:500 in the general population) that is heterogeneous with respect to disease-causing mutations, presentation, prognosis, and treatment strategies. Visibility attached to HCM relates largely to its recognition as the most common cause of sudden death in the young (including competitive athletes). Clinical diagnosis is by 2-dimensional echocardiographic identification of otherwise unexplained left ventricular wall thickening in the presence of a nondilated cavity. Overall, HCM confers an annual mortality rate of about 1% and in most patients is compatible with little or no disability and normal life expectancy. Subsets with higher mortality or morbidity are linked to the complications of sudden death, progressive heart failure, and atrial fibrillation with embolic stroke. Treatment strategies depend on appropriate patient selection, including drug treatment for exertional dyspnea (-blockers, verapamil, disopyramide) and the septal myotomy-myectomy operation, which is the standard of care for severe refractory symptoms associated with marked outflow obstruction; alcohol septal ablation and pacing are alternatives to surgery for selected patients. High-risk patients may be treated effectively for sudden death prevention with the implantable cardioverter-defibrillator.

Conclusions  Substantial understanding has evolved regarding the epidemiology and clinical course of HCM, as well as novel treatment strategies that may alter its natural history. An appreciation that HCM, although an important cause of death and disability at all ages, does not invariably convey ominous prognosis and is compatible with normal longevity should dictate a large measure of reassurance for many patients.

INTRODUCTION

Jump to Section  • Top  • Introduction  • Methods  • Results  • Author information  • References

Hypertrophic cardiomyopathy (HCM) is a complex and relatively common genetic cardiac disease that has been the subject of intense scrutiny and investigation for more than 40 years.^1-10 Hypertrophic cardiomyopathy is an important cause of disability and death in patients of all ages, although sudden and unexpected death in young people is perhaps the most devastating component of its natural history. Because of marked heterogeneity in clinical expression, natural history, and prognosis,^11-20 HCM often represents a dilemma to primary care clinicians and cardiovascular specialists, even to those for whom this disease is a focus of their investigative careers. Controversy abounds with regard to diagnostic criteria, clinical course, and management for which difficult questions often arise, particularly among practitioners infrequently engaged in the evaluation of HCM patients. Consequently, it is timely to place in perspective and clarify many of these relevant clinical issues and profile the rapidly evolving concepts regarding HCM.

METHODS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Author information  • References

A systematic search of the medical literature involving 968 articles primarily related to English-language HCM publications (1966-2000) from a varied and extensive number of authors and centers was conducted through MEDLINE or bibliographies of published articles. These studies and others before 1966 were analyzed to create a balanced appraisal of HCM.

Published accounts of HCM have come disproportionately from a relatively small group of highly selected centers in the United States, Canada, and Europe. In addition, perceptions emanating from the author's more than 25 years of extensive experience with HCM interfaced with the literature analysis. Many clinical HCM studies are observational and retrospective in design because of difficulty in organizing large prospective and randomized clinical trials for a disease with heterogeneous expression, selective referral patterns, and diverse mechanisms for morbidity and mortality. Therefore, in HCM, the level of evidence governing management decisions is derived primarily from nonrandomized studies. I placed the greatest reliance on evidence-based investigational designs and large, statistically powered and controlled studies, when available.

RESULTS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Author information  • References

Prevalence

Epidemiological investigations with diverse study designs have shown similar estimates for prevalence of phenotypically expressed HCM in the adult general population at about 0.2% (1:500).²⁰ Therefore, HCM is not rare and is the most common genetic cardiovascular disease, with reports from many countries. Nevertheless, a substantial proportion of individuals harboring a mutant gene for HCM are probably undetected clinically. Hypertrophic cardiomyopathy is, however, uncommon in routine cardiologic practice, affecting no more than 1% of outpatients.²¹ This limited exposure of clinicians to HCM understandably accounts for the uncertainty that prevails regarding this disease and its management.

Nomenclature

Since the first modern description in 1958,¹ HCM has been known by a confusing array of names, reflecting its clinical heterogeneity and the skewed experience of early investigators. Hypertrophic cardiomyopathy²² is the preferred name because it describes the overall disease spectrum without introducing misleading inferences that left ventricular (LV) outflow tract obstruction is an invariable feature (hypertrophic obstructive cardiomyopathy [HOCM] or idiopathic hypertrophic subaortic stenosis [IHSS]). Indeed, HCM is predominantly a nonobstructive disease; 75% of patients do not have a sizable resting outflow tract gradient.^3-4,7

Genetics

Hypertrophic cardiomyopathy is inherited as a mendelian autosomal dominant trait and caused by mutations in any 1 of 10 genes, each encoding proteins of the cardiac sarcomere (components of thick or thin filaments with contractile, structural, or regulatory functions).^{9, 11-13,23-27} The physical similarity of these proteins makes it possible to regard the diverse HCM spectrum as a single disease entity and primary sarcomere disorder. The mechanisms by which disease-causing mutations cause LV hypertrophy (LVH) and the HCM disease state are unresolved, although several hypotheses have been suggested.²⁸

Three of the HCM-causing mutant genes predominate, namely, -myosin heavy chain (the first identified), cardiac troponin T, and myosin-binding protein C. The other genes each account for a minority of HCM cases, namely, cardiac troponin I, regulatory and essential myosin light chains, titin, -tropomyosin, -actin, and -myosin heavy chain. This diversity is compounded by intragenic heterogeneity, with more than 150 mutations identified, most of which are missense with a single amino acid residue substituted with another.^{9, 11-13,26-27} Molecular defects responsible for HCM are usually different in unrelated individuals, and many other genes and mutations, each accounting for a small proportion of familial HCM, remain to be identified.

Contemporary molecular genetic studies throughout the past decade have provided important insights into the considerable clinical heterogeneity of HCM, including the preclinical diagnosis of affected individuals without phenotypic evidence of disease (ie, LVH by echocardiography or electrocardiography [ECG]).^{25, 29} Although DNA analysis for mutant genes is the definitive method for establishing the diagnosis of HCM, it is not yet a routine clinical strategy.⁹ Because of complex, time-consuming, and expensive techniques, genotyping is confined to research-oriented investigations of highly selected pedigrees. Development of rapid automated screening for genetic abnormalities will permit more widespread access to the power of molecular biology for resolving diagnostic ambiguities.

Recently, missense mutations in the gene that encodes the -2 regulatory subunit of the adenosine monophosphate–activated protein kinase (PRKAG2) have been reported to cause familial Wolff-Parkinson-White syndrome associated with conduction abnormalities and LVH^30-31 (because of glycogen accumulation in myocytes).³¹ This syndrome is most appropriately regarded as a metabolic storage disease distinct from HCM, which is caused by mutations in genes encoding sarcomeric proteins. Therefore, management and risk assessment of patients with Wolff-Parkinson-White syndrome and cardiac hypertrophy should not be predicated on data derived from patients with HCM.

Of potential importance for understanding HCM pathophysiology are genetic animal models (ie, transgenic mice and rabbits)^32-35 and spontaneously occurring animal diseases.³⁶ In particular, domestic cats with heart failure commonly show a disease with clinical and morphologic features remarkably similar to HCM in humans.³⁶

Diagnosis

Clinical diagnosis of HCM is established most easily and reliably with 2-dimensional echocardiography^{6, 9-10,14-16,19-21,25, 37-42} by imaging the hypertrophied but nondilated LV chamber, in the absence of another cardiac or systemic disease (eg, hypertension or aortic stenosis) capable of producing the magnitude of hypertrophy evident (Figure 1 and Figure 2A).^{19, 22} Hypertrophic cardiomyopathy may be initially suspected because of a heart murmur (occasionally during preparticipation sports examinations),⁴³ positive family history, new symptoms, or abnormal ECG pattern.^{2, 44-45} Across the broad disease spectrum of HCM, the physical examination may not be a reliable method for clinical identification, given that most patients do not have LV outflow tract obstruction and most of the well-documented physical findings (eg, loud systolic heart murmur and bifid arterial pulse) are limited to patients with outflow gradients.

View larger version (84K): [in this window] [in a new window] Figure 1. Heterogeneity in the Pattern and Extent of Left Ventricular (LV) Wall Thickening in HCM Echocardiographic parasternal long-axis stop-frame images obtained in diastole showing A, massive asymmetric hypertrophy of ventricular septum (VS) with wall thickness >50 mm; B, pattern of septal hypertrophy in which the distal portion is considerably thicker than the proximal region at mitral valve level; C, hypertrophy sharply confined to basal (proximal) septum just below aortic valve (arrows); D, hypertrophy confined to LV apex (asterisk), consistent with the designation of apical hypertrophic cardiomyopathy (HCM); E, relatively mild hypertrophy in a concentric (symmetric) pattern with each segment of ventricular septum and LV free wall showing similar or identical thicknesses (paired arrows); F, inverted pattern of hypertrophy in which anterior VS is less substantially thickened than the posterior free wall (PW), which is markedly hypertrophied (ie, 40 mm). Calibration marks are 1 cm apart. Ao indicates aorta; AML, anterior mitral leaflet; and LA, left atrium. Reproduced from Klues et al19 with the permission of Elsevier Science, Inc.

View larger version (117K): [in this window] [in a new window] Figure 2. Morphologic Features of the Myocardial Substrate for Sudden Death in Hypertrophic Cardiomyopathy (HCM) A, Gross heart specimen from a 13-year-old male competitive athlete showing disproportionate thickening of the ventricular septum (VS) with respect to the left ventricular (LV) free wall (RV indicates right ventricular wall); B, marked disarray of cardiac muscle cells in the disproportionately thickened VS with adjacent hypertrophied cells arranged in a chaotic pattern at oblique and perpendicular angles, forming the typical disorganized architecture of HCM; C, LV myocardium showing several abnormal intramural coronary arteries with markedly thickened walls and narrowed lumen, dispersed within replacement fibrosis (hematoxylin and eosin stain in B and C; original magnifications x50). Adapted from Maron BJ. Hypertrophic cardiomyopathy. Current Probl Cardiol. 1993;18:637-704 with permission of Mosby Inc.

With regard to pedigree assessment, it is obligatory for the proband to be informed of the familial nature and autosomal dominant transmission of HCM. Screening of first-degree relatives, including history taking and physical examinations, and 2-dimensional echocardiography and ECG should be encouraged, particularly if adverse HCM-related events have occurred in the family.

In clinically diagnosed patients, increased LV wall thicknesses range widely from mild (13-15 mm)^{3, 7, 46} to massive (30 mm [normal, 12 mm]),^{39, 41-42,47} including the most substantial in any cardiac disease, namely, up to 60 mm (Figure 1).⁴⁰ In trained athletes, modest segmental wall thickening (ie, 13-15 mm) raises the differential diagnosis between extreme physiologic LVH (ie, athlete's heart) and mild morphologic expressions of HCM,⁴⁸ which can usually be resolved with noninvasive testing.⁴⁹ Magnetic resonance imaging may be of diagnostic value when echocardiographic studies are technically inadequate or in identifying segmental LVH undetectable by echocardiography.

The 12-lead ECG pattern is abnormal in 75% to 95% of HCM patients and typically demonstrates a wide variety of patterns.^{25, 44, 50} Normal ECGs are most commonly encountered in family members identified as part of pedigree screening or when associated with mild localized LVH.^{25, 44, 50} Only a modest relation between ECG voltages and the magnitude of LVH assessed by echocardiography is evident. Nevertheless, ECGs have diagnostic value in raising a suspicion of HCM in family members without LVH on echocardiogram and in targeting athletes for diagnostic echocardiography as part of preparticipation screening.

However, not all individuals harboring a genetic defect will express the clinical features of HCM, such as LVH by echocardiography, abnormal ECG results, or cardiac symptoms.^{3, 9, 13, 25, 29, 51-53} Molecular genetic studies have, in fact, demonstrated that there is no minimum wall thickness required for HCM at a given time in life, and it is not unusual for children younger than 13 years to carry a mutant HCM gene without LVH, underscoring the lack of productivity in preadolescent echocardiographic screening.^{7, 9, 11-13,23-25,29, 51, 53-56} Substantial LV remodeling with spontaneous appearance of hypertrophy typically occurs with accelerated body growth during adolescence, and morphologic expression is usually completed at physical maturity (about 17-18 years of age).^{52, 57-58} Abnormalities on 12-lead ECG and non–preload-dependent measures of diastolic dysfunction with tissue Doppler ultrasonography may precede the appearance of hypertrophy, providing clues to impending LVH.^{25, 29, 51, 54, 56, 58-59}

Novel diagnostic criteria for HCM have recently emerged and are based on genotype-phenotype studies showing incomplete disease expression with absence of LVH in adult individuals, most commonly due to cardiac myosin-binding protein C or troponin T mutations.^{13, 23-25,60} In both cross-sectional and serial echocardiographic studies, mutations in the myosin-binding protein C gene may demonstrate age-related penetrance of the HCM phenotype in which delayed de novo onset of LVH may occur in midlife and later.^{13, 25, 53-54} Such adult morphologic conversions dictate that it is no longer possible to use a normal echocardiogram to offer definitive reassurance at maturity (or even in middle age) that asymptomatic family members are free of a disease-causing mutant HCM gene^{13, 25, 60-61}; this observation probably necessitates a strategy of postadolescent echocardiographic examinations every 5 years.

Paradoxically, a small distinctive subset of HCM patients (ie, about 5%-10%) evolve into the end stage (or "burned-out" phase) characterized by LV wall thinning, cavity enlargement, and systolic dysfunction often resembling dilated cardiomyopathy and producing relentlessly progressive and irreversible heart failure.^{3-4,7, 58, 62} It is also possible that other adults experience subtle regression in wall thickness with aging (not linked with clinical deterioration), reflecting gradual, widespread remodeling.^{58, 63} Therefore, the HCM phenotype is not a static disease manifestation; LVH can appear at virtually any age and increase or decrease dynamically throughout life.

HCM Phenotype and Morphologic Features

Left Ventricular Hypertrophy. Structural heterogeneity in HCM is considerable, with no single pattern of LVH regarded as typical (Figure 1).^{3, 6, 15, 19, 23, 41, 47} Although many patients show diffusely distributed LVH, almost one third have mild wall thickening localized to a single segment,^{15, 19, 46} including the apical form^{37-39,61, 64} that appears most commonly in Japanese people (Figure 1D).⁶⁴ Left ventricular hypertrophy is characteristically asymmetric, with the anterior septum usually predominant (Figure 1A-D, Figure 1F; Figure 2A), although a few patients show a symmetric (concentric) pattern (Figure 1E).^15-16,19 Distribution of LV wall thickening shows no direct linkage to outcome, although distal hypertrophy is associated with the absence of obstruction.^{15, 19} Young children may present with LVH resembling HCM as part of other disease states (eg, Noonan syndrome, mitochondrial myopathies, and metabolic disorders) unrelated to HCM-causing sarcomere protein mutations. Other markers of HCM that are not obligatory prerequisites for diagnosis include a hypercontractile LV and dynamic subaortic obstruction typically produced by mitral valve systolic anterior motion and septal contact^{6, 8, 65-70} (caused by drag effect⁶⁹ or possibly the Venturi phenomenon^{6, 8, 67-68,70}), which is responsible for a loud systolic murmur.

Cellular Components. Cardiomyopathic substrate in HCM is defined anatomically by several histological features based on autopsy observations. Left ventricular myocardial architecture is disorganized, composed of hypertrophied cardiac muscle cells (myocytes) with bizarre shapes and multiple intercellular connections often arranged in chaotic alignment at oblique and perpendicular angles (Figure 2B).^{1, 71-75} Cellular disarray may be widely distributed, occupying substantial portions of LV wall (average, 33%), and is more extensive in young patients who die of their disease.^{72, 74-75}

Abnormal intramural coronary arteries, characterized by thickened walls with increased intimal and medial collagen and narrowed lumen, may be regarded as a form of small vessel disease (Figure 2). ^76-77 Such architectural alterations of the microvasculature, as well as the mismatch between myocardial mass and coronary circulation, are likely responsible for impaired coronary vasodilator reserve^78-79 and bursts of myocardial ischemia^78-90 leading to myocyte death and repair in the form of patchy or transmural replacement scarring (Figure 2).^{73, 76, 83-85,90} Such myocardial scarring supports clinical evidence that ischemia frequently occurs within the natural history of HCM^{2-8,78, 82, 86-89,91-93} and may serve as the substrate for premature heart failure–related death.⁷⁴ It is also evident that the cardiomyopathic process in HCM is not confined to areas of gross wall thickening and that nonhypertrophied regions also contribute to ischemia or impaired diastolic function.^{86, 88-89,91, 94-96}

Disorganized cellular architecture,^{1, 71-73,75} myocardial scar-ring,^{73, 76, 83-85,90} and expanded interstitial (matrix) collagen^{83, 97} probably serve as arrhythmogenic substrates predisposing to life-threatening electrical instability. This substrate is likely the source of primary ventricular tachycardia and ventricular fibrillation, which appear to be the predominant mechanisms of sudden death,^98-101 either primarily or in association with triggers intrinsic to the disease process, namely, myocardial ischemia, systemic hypotension, supraventricular tachyarrhythmias, or environmental variables (eg, intense physical exertion).

Penetrance and variability of phenotypic expression are undoubtedly influenced by factors other than disease-causing mutant genes such as modifier genes (eg, angiotensin-converting enzyme genotype),^102-103 coexistent hypertension, or lifestyle. Indeed, several phenotypic manifestations of HCM do not primarily involve sarcomeric proteins, including increased interstitial collagen,^{83, 97} abnormal intramural arteries,^76-77 and mitral valve malformations such as elongated leaflets^{18, 104} or direct papillary muscle insertion into the mitral valve.¹⁷

Clinical Course

Hypertrophic cardiomyopathy is unique among cardiovascular diseases by virtue of its potential for clinical presentation during any phase of life (from infancy to >90 years of age).^{1-8,19-20,51-52,54, 98-99,105-115} Although adverse clinical consequences have been recognized for many years, particularly sudden cardiac death,^{1-2,5-8,116-119} a more balanced perspective regarding prognosis has evolved recently.^{111, 114, 120-127}

Historically, misperceptions regarding the clinical significance of HCM have prevailed because of its relatively low prevalence in cardiac populations,^20-21 extreme heterogeneity,^{3, 6} and skewed patterns of patient referral that created important selection biases.^{111, 121-122} Indeed, much of the data assembled throughout the past 40 years have been disproportionately generated by a few tertiary centers largely composed of patients preferentially referred because of their high-risk status or severe symptoms requiring specialized care such as surgery.^{111, 121-122} Hence, the older literature was dominated by the most adverse consequences of HCM, while clinically stable, asymptomatic, and elderly patients were underrepresented.^{105, 112-115,121}

Consequently, the risks of HCM would appear to have been overestimated by dependence on frequently cited, ominous mortality rates of 3% to 6% annually.^{108, 119} These figures, based largely on skewed tertiary-center experience, have contributed greatly to the misguided perception that HCM is a generally unfavorable disorder. Recent reports throughout the last 7 years from less selected regional or community-based HCM patient cohorts cite much lower annual mortality rates, about 1%,^120-126 not dissimilar to that for the general adult US population.¹¹¹ Such data provide a more balanced view in which HCM may be associated with important symptoms and premature death but more frequently with no or relatively mild disability and normal life expectancy.^{105, 111, 113, 115, 123-124}

Elderly HCM patients (75 years) have been reported to compose as much as 25% of an HCM cohort, with only a minority having severe manifestations of heart failure.¹¹¹ Outflow obstruction is commonly evident in patients of advanced age (ie, in about 40%), suggesting that subaortic gradients may be well tolerated for long periods without adverse consequences. Indeed, HCM in elderly patients can be a genetic disorder caused by dominant sarcomere protein mutations most commonly in cardiac myosin-binding protein C and troponin I genes.¹²⁸

Profiles of Prognosis and Treatment Strategies

The clinical course for individual HCM patients is most appropriately viewed in terms of specific subgroups rather than only from perceptions of the overall disease spectrum (Figure 3). Some patients progress along certain relatively discrete, adverse pathways: (1) high risk for sudden death^{1-8,11-12,24, 41-43,47, 98-99,101, 108, 114, 116-118,127} (2) congestive symptoms of heart failure with exertional dyspnea and functional disability often associated with chest pain and usually in the presence of preserved LV systolic function^{111, 119-120}; and (3) consequences of atrial fibrillation (AF),^129-131 including embolic stroke.

View larger version (95K): [in this window] [in a new window] Figure 3. Primary Treatment Strategies for Subgroups Within the Hypertrophic Cardiomyopathy Clinical Spectrum Hypertrophic cardiomyopathy (HCM) clinical subgroups are not necessarily mutually exclusive; overlap or progression from one subgroup to another may occur (thin solid and dashed arrows). Most patients with HCM who are at high risk of sudden death or who develop atrial fibrillation are initially in the "None or Mild Symptoms" clinical subgroup. Asterisk indicates that patients with a positive genotype and negative phenotype may subsequently show morphologic conversion to the HCM phenotype with left ventricular hypertrophy (usually in adolescence, but also in mid-life or later). Dagger indicates that drug therapy may include -blockers, calcium channel blockers (particularly verapamil), disopyramide, as well as diuretic agents. Double dagger indicates that for major interventions, obstructive HCM is generally regarded as a left ventricular outflow gradient of approximately 50 mm Hg at rest or with provocative maneuvers; in this context, nonobstructive HCM is regarded as a left ventricular outflow gradient of less than approximately 30 to 50 mm Hg at rest as well as with provocative maneuvers. Width of the arrows from the overall HCM population represent the approximate relative proportion of patients with HCM within each major clinical subgroup. Adapted from Spirito et al7 with permission of the Massachusetts Medical Society.

Sudden Death. Risk Stratification. Sudden death is the most common mode of demise and the most devastating and unpredictable complication of HCM.^{1-4,7-8,98-100,114} Therefore, within the broad HCM disease spectrum, for which overall annual mortality rate is about 1%, exist small subsets at a much higher risk (perhaps at least 5% annually).

An important but complex objective has been the identification of such higher-risk individuals among the vast HCM spectrum. For example, sudden death can be the initial manifestation of HCM, and such patients usually have no or only mild prior symptoms. Although sudden death occurs most commonly in children and young adults, risk extends across a wide age range through midlife and beyond¹¹⁴; therefore, achieving a particular age does not confer immunity to sudden catastrophe. Sudden death occurs most commonly during mild exertion or sedentary activities but is not infrequently related to vigorous physical exertion.^{43, 114, 118} Indeed, HCM is the most common cause of cardiovascular sudden death in young people, including trained competitive athletes (most commonly in basketball and football and in black athletes).⁴³

The majority of HCM patients (55%) do not demonstrate any of the acknowledged risk factors in this disease, and it is exceedingly uncommon for such patients to die suddenly⁴⁷; the subset at increased risk appears to comprise about 10% to 20% of the HCM population.⁴⁷ Highest risk for sudden death in HCM has been associated with any of the following noninvasive clinical markers (Figure 3)^{3, 7, 9, 40-42,47, 98, 101, 111, 116-119,127, 132-136} prior cardiac arrest or spontaneous sustained ventricular tachycardia; family history of premature HCM-related death, particularly if sudden, in close relatives, or multiple; syncope and some cases of near-syncope, particularly when exertional or recurrent, or in young patients when documented as arrhythmia-based or clearly unrelated to neurocardiogenic mechanisms; multiple and repetitive or prolonged bursts of nonsustained ventricular tachycardia on serial ambulatory (Holter) ECG recordings; hypotensive blood pressure response to exercise, particularly in patients younger than 50 years; and extreme LVH with maximum wall thickness 30 mm, particularly in adolescents and young adults.

The latter risk factor emanates from a continuous, direct relationship between maximum LV wall thickness and sudden death, which supports the magnitude of LVH as a determinant of prognosis in HCM.^{6, 41-42,47} Exceptions to that association are a few highly selected HCM families with multiple sudden deaths and mild LVH caused by troponin T mutations.^23-24,60 Description of the total HCM risk profile is probably incomplete, and no single disease feature or test is capable of stratifying risk in all patients.

There is only a suggested association^{41, 111, 127} but no clinically relevant and independent linkage between sudden death and outflow obstruction,^{3, 7, 41, 111, 114, 120, 137} although data on particularly large (100 mm Hg) gradients are limited.^{111, 127} One report suggests that short, tunneled (bridged) segments of left anterior descending coronary artery, mediated by ischemia, independently convey increased risk for cardiac arrest in children with HCM.¹³⁸

Presentation of HCM in young children is exceedingly uncommon and usually creates a clinical dilemma because of diagnosis (often fortuitous) so early in life and the uncertainty regarding risk over such long periods.^{89, 96-98} Studies of HCM in children report annual mortality rates of 2% (community-based populations)¹⁰¹ to 6% (tertiary referral cohorts).^{98, 107-109}

It has been proposed, based on genotype-phenotype correlations, that the genetic defects responsible for HCM^{3, 7, 9, 11-13,23-27,139} could represent the primary determinant and stratifying marker for sudden death risk, with specific mutations conveying either favorable or adverse prognosis.¹⁴⁰ For example, some -myosin heavy chain mutations (eg, Arg403Gln and Arg719Gln) and some troponin T mutations may be associated with a higher frequency of premature death compared with other mutations, such as those of myosin-binding protein C (InsG791) or -tropomyosin (Asp175Asn).^{3, 7, 9, 11-13,23-24,26-27} However, caution is warranted before strong conclusions are drawn regarding prognosis based solely on the available epidemiologic genetic data, which are relatively limited and skewed by virtue of selection bias toward high-risk families.^{9, 139} Access to the molecular biology of HCM does not yet represent a clinically relevant strategy that routinely affects disease management.

Prognosis attached to adult gene carriers without LVH appears to be mostly benign.^{13, 25, 53-54} There is no available evidence to justify routinely precluding genotype positive–phenotype negative individuals of any age from most activities or employment opportunities.⁹

The role of invasive strategies such as electrophysiologic testing with programmed ventricular stimulation and the significance of induced arrhythmias in detecting the substrate for ventricular fibrillation in individual HCM patients are unresolved.^141-142 Limitations include the infrequency with which monomorphic ventricular fibrillation is provoked and the nonspecificity of rapid polymorphic ventricular tachycardia and ventricular fibrillation.¹⁴²

Although attention has understandably focused on high-risk HCM patients, the absence of risk factors and certain clinical features can be used to develop a profile of HCM patients at low likelihood for sudden death caused by life-threatening rhythm disturbances, as well as other adverse events (eg, at a rate of <1% annually).⁷ Adult patients most likely at lowest risk are those with no or only mild congestive symptoms in the absence of the following: family history of HCM-related premature death; syncope (or near-syncope) judged unlikely to be neurocardiogenic in origin; nonsustained ventricular tachycardia during ambulatory Holter ECGs; marked LV outflow gradient of at least 50 mm Hg; substantial LVH (wall thickness 20 mm); left atrial enlargement (>45 mm); and hypotensive blood pressure response to exercise.^{3-4,6-13,23-24,26-27,41-42,47, 134-136,139-141} Such patients with favorable prognosis constitute an important proportion of the overall HCM population and generally deserve a measure of reassurance regarding their disease.^{3, 7}

Most HCM patients should undergo a risk stratification assessment (probably with the exception of patients older than 60 years) that requires, in addition to careful history taking and physical examination, noninvasive testing with 2-dimensional echocardiography, 24- or 48-hour ambulatory Holter ECGs, and treadmill (or bicycle) exercise testing. Such evaluation and follow-up should be carried out by (or involve) qualified specialists in cardiovascular medicine.

Prevention. In HCM, treatment strategies to reduce risk for sudden death have been historically predicated on drugs such as -blockers, verapamil, and antiarrhythmic agents (ie, quinidine, procainamide, and amiodarone).^{4, 116-117,143-145} Nevertheless, there is little evidence¹⁴⁴ that prophylactic pharmacological strategies and rhythm-modulating drugs effectively reduce risk for sudden death; furthermore, because of its potential toxicity, amiodarone is unlikely to be tolerated throughout the long risk periods characteristic of young HCM patients. Therefore, there would appear to be little justification for prophylactic drug treatment in asymptomatic HCM patients, whether or not they are judged to be at high risk.¹⁴³

At present, the implantable cardioverter-defibrillator (ICD) appears to be the most effective treatment modality for the high-risk HCM patient, with the potential to alter natural history (Figure 3).^98-100 In a large multicenter study, ICDs aborted potentially lethal ventricular tachyarrhythmias and restored sinus rhythm in almost 25% of patients throughout a brief 3-year follow-up.⁹⁸ Appropriate device interventions occurred at 11% annually for secondary prevention (implant following cardiac arrest) and 5% annually for primary prevention (implant based on risk factors), usually in patients with no or only mild prior symptoms.⁹⁸ Patients receiving appropriate shocks were young (mean, 40 years), and ICDs often remained dormant for prolonged periods before discharging (up to 9 years), emphasizing the unpredictability of sudden death events in HCM.

Sudden death prevention with the ICD is most strongly warranted for patients with prior cardiac arrest or sustained spontaneous ventricular tachycardia. Although multiple risk factors convey increasingly greater sudden-death risk,⁴⁷ a single major risk factor in an individual patient may be sufficient to justify strong consideration for primary prevention with an ICD. Nevertheless, uncertainty persists regarding precisely which HCM patients with only 1 risk factor should be candidates for prophylactic ICD treatment,^41-42,98 and therefore individual clinical judgment taking into account the overall clinical profile, including age, apparent strength of the risk factor identified, and the level of risk acceptable to the patient and family, may be necessary to definitively resolve many of these clinical decisions. Also, physician and patient attitudes toward ICDs (and also access to the devices) can vary considerably among countries and cultures and profoundly affect clinical decision making.^{42, 98, 146}

Intense physical exertion constitutes a sudden-death trigger in susceptible individuals.⁴³ Therefore, to reduce risk, disqualification of athletes with unequivocal evidence of HCM from most competitive sports has been prudently recommended by a national consensus panel.¹⁴⁷

Atrial Fibrillation. Atrial fibrillation is the most common sustained arrhythmia in HCM, accounting for unexpected hospital admissions and unscheduled work loss, and therefore usually justifies aggressive therapeutic strategies (Figure 3). Paroxysmal episodes or chronic AF ultimately occur in 20% to 25% of HCM patients, increase in incidence with age, and are linked to left atrial enlargement.^{111, 120, 129-131} Atrial fibrillation is reasonably tolerated by about one third of patients and is not an independent determinant of sudden death.¹³⁰ However, AF is associated with embolic stroke (incidence, about 1% annually; prevalence, 6%), leading to death and disability most frequently in the elderly,¹³¹ as well as progressive heart failure, particularly when AF onset occurs before 50 years of age and is associated with basal outflow obstruction.¹³⁰

Paroxysmal AF may be responsible for acute clinical decompensation, requiring electrical or pharmacological cardioversion.^{4, 7-8} Although data in HCM patients are limited, amiodarone is regarded as effective for reducing AF recurrences. In chronic AF, -blockers and verapamil effectively control heart rate, although A-V node ablation with permanent ventricular pacing may occasionally be necessary. Because of the potential for clot formation and embolization, anticoagulant therapy with warfarin is indicated in patients with either recurrent or chronic AF. Since 1 or 2 paroxysms of AF have been associated with the risk for systemic thromboembolism in HCM, the threshold for initiation of anticoagulant therapy should be low.^130-131 However, such clinical decisions should be tailored to the individual patient after the obligatory lifestyle modifications, risk of hemorrhagic complications, and expectations for compliance have been considered.

Heart Failure. Presentation. Symptoms such as exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and fatigue are common, characteristically in the presence of normal or supranormal LV contractility and independent of whether outflow obstruction is present (Figure 3).^2-8,148-154 Such symptoms of HCM-related heart failure are usually deferred until adulthood but may occur at any age.

Marked symptom progression (to New York Heart Association classes III and IV) is relatively infrequent, developing in about 15% to 20% of an unselected population, and such exertional disability may evolve at varying rates; deterioration is often gradual and punctuated with long periods of stability and day-to-day variability (Figure 3).^2-3,7

Congestive symptoms and exertional limitation in HCM appear to be largely the consequence of diastolic dysfunction in which impaired LV relaxation, increased chamber stiffness, and compromised left atrial systolic function impede filling, leading to elevated left atrial and LV end-diastolic pressures with reduced stroke volume and cardiac output. These mechanisms result in pulmonary congestion with diminished exercise performance^148-154 evidenced by reduced peak oxygen consumption.¹⁵⁵ However, heart failure related to diastolic dysfunction may also be intertwined with other pathophysiological mechanisms such as myocardial ischemia, outflow obstruction, and AF.^{3, 7, 130}

Chest pain suggestive of myocardial ischemia (with angiographically normal coronary arteries), either typical or atypical of angina, is a symptom commonly associated with exertional dyspnea.^{2-8,85, 91-93} Myocardial perfusion defects, net lactate release during atrial pacing, and blunted coronary flow reserve constitute evidence of ischemia likely caused at least in part by an abnormal microvasculature.^{76-82,84, 86-88,156-157} The role of ischemia in risk stratification is unresolved, in part because the clinical assessment of ischemia (and that of diastolic dysfunction) have been limited by an inability to noninvasively measure these abnormalities with quantitative precision.

Drug Treatment Strategies. If exertional symptoms of heart failure intervene, it is conventional to initiate pharmacological therapy with negative inotropic drugs such as -adrenergic blockers or verapamil, independent of whether outflow obstruction is present (Figure 3).^{2-8,10, 158-162} Patients who do not experience improvement of symptoms with one drug may subsequently benefit from the other, but combined administration is not advantageous.⁴ However, verapamil may be deleterious to some patients with severe outflow gradients and heart failure,^{8, 163} and some investigators favor disopyramide (often with a -blocker) for such severely symptomatic patients with obstruction and verapamil or -blockers in patients who do not develop obstruction.^164-166 There are comparatively few data available regarding the use of other calcium channel blockers such as diltiazem in HCM for relief of symptoms. Patients who develop severe symptoms of heart failure associated with systolic dysfunction and deteriorate into the end stage require alternative drug treatment with diuretics, vasodilators, and digitalis.^{3-4,7-8,61, 167}

-Blockers may mitigate predominantly provocable gradients (induced with interventions such as physiologic exercise or Valsalva maneuver, isoproterenol infusion, or amyl nitrite inhalation),² and disopyramide may reduce some subaortic gradients at rest,^164-166 mediated by ventricular afterload reduction and slowing of the LV ejection acceleration.¹⁶⁶ For patients with outflow obstruction, risk for bacterial endocarditis (usually involving the mitral valve) dictates prophylactic administration of antimicrobial drugs, primarily to patients with obstruction, before dental procedures or surgery.¹⁶⁸

Surgical Treatment. Should severe heart failure–related symptoms become unrelenting and refractory to pharmacological treatment, and lifestyle unacceptable, subsequent therapeutic decisions are determined largely by whether basal obstruction to LV outflow is present (peak instantaneous gradient 50 mm Hg) (Figure 3).^3-4,6-8 Throughout the past 40 years, the experience of many centers worldwide has caused the ventricular septal myotomy-myectomy operation (Morrow procedure) to become established as the standard therapeutic option (ie, "gold standard") for adults and children with obstructive HCM and severe drug-refractory symptoms.^{3, 6-8,169-184} However, operative candidates represent only a small (5%) although important subset of the overall HCM population.⁷

Operation requires resection of a small amount of muscle (about 5 g) from the proximal septum extending just beyond the distal margins of mitral leaflets, thereby abolishing any significant impedance to LV outflow.¹⁶⁹ Other surgeons have used a low-profile mitral valve prosthesis in patients judged to have unfavorable septal morphology^174-175 or with intrinsic mitral valve disease (such as myxomatous degeneration) accounting for severe mitral regurgitation.^{183, 185} Papillary muscle insertion directly into the mitral valve, producing muscular midcavity obstruction, requires distally extended septal resection or valve replacement.^{17, 180}

Myotomy-myectomy performed at experienced surgical centers in the absence of associated conditions has acceptably low operative mortality (2%). Most patients (about 70%) achieve subjective improvement in symptoms and exercise capacity 5 years or longer after their operation and often for extended periods. Improved metabolic and hemodynamic measures¹⁸⁶ associated with symptomatic benefit following myotomy-myectomy appear to be largely the consequence of abolition or substantial reduction in basal outflow gradient^170-184 and normalization of LV pressures (in >90% of patients),^{3, 6-8,169-183} as well as alleviation of the mild to moderate mitral regurgitation that is secondary to obstruction.¹⁸³ Patients in whom severe refractory symptoms can be linked to large outflow gradients present only under provocable conditions, such as elicited physiologically with exercise, may also benefit from myotomy-myectomy.¹⁷⁵

Consistent relief of severe symptoms following surgery is evidence that marked outflow gradients and increased LV systolic pressure are of clinical significance to many patients. However, outflow obstruction is not deleterious to all patients, since it is now evident that large gradients may be tolerated for long periods with no or little disability.¹¹¹ Consequently, although the outflow gradient is a highly visible and quantifiable component of HCM, it is also typically labile and hemodynamically sensitive to alterations in ventricular volume and systemic vascular resistance,^{2, 4-5,187-189} even after standing or a heavy meal, and should not be regarded as equivalent to the disease itself.^190-191 Although major interventions can be advantageous by reducing the outflow gradient when it is judged to be persistent and the cause of severe symptoms, the presence per se of subaortic obstruction unassociated with marked disability is rarely the sole justification for such treatment.¹⁹¹

Alternatives to Surgery. Some operative candidates may not have ready access to major centers experienced with myotomy-myectomy because of geographical factors, or they may not be regarded as favorable operative candidates because of concomitant medical conditions, advanced age, prior cardiac surgery, or insufficient motivation.⁷

Therefore, 2 treatment options have emerged as potential alternatives to surgery for selected patients (Figure 3). First, in uncontrolled and observational studies, chronic dual-chamber pacing was associated with amelioration of symptoms and reduction of outflow gradient in many HCM patients.^192-194 However, several randomized crossover clinical trials reported that subjective symptomatic benefit during pacing frequently occurs with little objective evidence of improved exercise capacity^195-199 and can be largely explained as a placebo effect.^{192, 195-196,198} Although pacing is not a primary treatment for HCM, 1 study showed that elderly patients (older than 65 years), a subgroup for which alternatives to surgery are often desirable, experienced objective improvement in symptoms with pacing.¹⁹⁵ While myotomy-myectomy provides superior results to pacing in most patients,¹⁸¹ a dual-chamber pacing trial prior to myotomy-myectomy could be of value in selected candidates, given that pacing (1) is implicitly less invasive than surgery or alcohol septal ablation, (2) is a more widely accessible method to the practicing cardiologist, (3) can permit more aggressive drug treatment by obviating concern for drug-induced bradycardia, (4) may be withdrawn, and (5) does not obviate subsequent implementation of invasive procedures. Pacing does not reduce sudden-death risk significantly^{193, 195} or trigger LV remodeling.¹⁹⁵

A second alternative therapy to surgery is the recently developed alcohol septal ablation technique, which is a percutaneous coronary artery intervention using methods and technology available for atherosclerotic coronary artery disease.^200-205 Absolute alcohol (about 1-4 mL) is introduced into the target septal perforator coronary artery branch to produce myocardial infarction, which in turn reduces basal septal thickness and motion, enlarges the LV outflow tract, and decreases mitral valve systolic anterior motion, thereby mimicking the hemodynamic consequences of myotomy-myectomy.^200-207 Indeed, reductions in outflow gradient associated with alcohol septal ablation have been reported to be similar to those resulting from myotomy-myectomy,²⁰⁵ although a recent comparative analysis showed surgery to be superior to ablation in reducing resting and provocable gradients.²⁰⁷ Also, similar proportions of ablation and surgical patients have been reported to show subjective^200-203,205 and objective²⁰⁴ improvements in congestive symptoms and quality of life over relatively short periods, largely in observational studies; in addition, there are unconfirmed claims of diffuse regression of LVH following ablation.²⁰⁴ However, alcohol septal ablation in HCM has not yet been subjected to the scrutiny of randomized or controlled studies.^{191, 206}

Septal ablation is associated with operative morbidity and mortality, similar to that of myotomy-myectomy; complications include permanent pacemaker for high-grade A-V block, coronary dissection, and large anterior infarction.^200-203,205 In contrast to that for surgery, the postprocedural follow-up for alcohol septal ablation is relatively brief (about 3-5 years compared with 40 years for myotomy-myectomy).¹⁹¹

Furthermore, ablation alone potentially creates a permanent, electrically unstable substrate for lethal reentrant ventricular tachyarrhythmias by virtue of the healed intramyocardial septal scar in some HCM patients who are already undoubtedly predisposed to arrhythmogenesis; this consideration raises some uncertainty regarding the long-term risks of alcohol septal ablation.¹⁹¹

Heart Transplantation. Therapeutic options are considerably limited for patients who have the nonobstructive form of HCM and experience drug-refractory severe symptoms, including those in the end-stage phase.⁶¹ This subset of patients, among the broad HCM spectrum, may become candidates for heart transplantation.^61-62

AUTHOR INFORMATION

Jump to Section  • Top  • Introduction  • Methods  • Results  • Author information  • References

Funding/Support: This work was supported by grants from the Minneapolis Heart Institute Foundation and Paul G. Allen Foundations.

Corresponding Author and Reprints: Barry J. Maron, MD, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 60, Minneapolis, MN 55407 (e-mail: hcm.maron{at}mhif.org).

Author Affiliation: Minneapolis Heart Institute Foundation, Minneapolis, Minn.

REFERENCES

Jump to Section  • Top  • Introduction  • Methods  • Results  • Author information  • References

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1-18. FREE FULL TEXT 2. Braunwald E, Lambrew CT, Rockoff D, et al. Idiopathic hypertrophic subaortic stenosis, I: a description of the disease based upon an analysis of 64 patients. Circulation. 1964;30(suppl IV):3-217. 3. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997;350:127-133. FULL TEXT | ISI | PUBMED 4. Maron BJ, Bonow RO, Cannon III RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780-789, 844-852. ISI | PUBMED 5. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation. 1968;37:759-788. FREE FULL TEXT 6. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy. Prog Cardiovasc Dis. 1985;28:1-83. FULL TEXT | ISI | PUBMED 7. Spirito P, Seidman CE, McKenna WJ, Maron BJ. Management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785. FREE FULL TEXT 8. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92:1680-1692. FREE FULL TEXT 9. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrme, and Marfan syndrome. A statement for healthcare professions from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association. Circulation. 1998;98:1460-1471. FREE FULL TEXT 10. Louie EK, Edwards LC. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 1994;36:275-308. ISI | PUBMED 11. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995;92:1336-1347. FREE FULL TEXT 12. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995;91:532-540. FREE FULL TEXT 13. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for human cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248-1257. FREE FULL TEXT 14. Ciro E, Nichols III PF, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Circulation. 1983;67:1227-1233. FREE FULL TEXT 15. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1981;48:418-428. FULL TEXT | ISI | PUBMED 16. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1983;2:437-444. ABSTRACT 17. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Circulation. 1991;84:1188-1197. FREE FULL TEXT 18. Klues HG, Maron BJ, Dollar AL, et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85:1651-1660. FREE FULL TEXT 19. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1995;26:1699-1708. ABSTRACT 20. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Circulation. 1995;92:785-789. FREE FULL TEXT 21. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994;73:577-580. FULL TEXT | ISI | PUBMED 22. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242-1244. FULL TEXT | ISI | PUBMED 23. Watkins H, McKenna WJ, Thierfelder L, et al. The role of cardiac troponin T and -tropomyosin mutations in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058-1064. FREE FULL TEXT 24. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997;29:549-555. ABSTRACT 25. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C mutations. J Am Coll Cardiol. 2001;38:315-321. FREE FULL TEXT 26. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114. ABSTRACT 27. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel -cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994;93:280-285. ISI | PUBMED 28. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58-60. FULL TEXT | ISI | PUBMED 29. Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753-1760. ABSTRACT 30. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344:1823-1831. FREE FULL TEXT 31. Arad M, Benson DW, Perez-Atayde, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002;109:357-362. FULL TEXT | ISI | PUBMED 32. Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 1996;272:731-734. ABSTRACT 33. Marian AJ, Wu Y, Lim DS, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest. 1999;104:1683-1692. ISI | PUBMED 34. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest. 1998;102:1292-1300. ISI | PUBMED 35. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791. FREE FULL TEXT 36. Fox PR, Liu S-K, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. Circulation. 1995;92:2645-2651. FREE FULL TEXT 37. Webb JG, Sasson Z, Rakowski H, et al. Apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990;15:83-90. ABSTRACT 38. Louie EK, Maron BJ. Apical hypertrophic cardiomyopathy: clinical and two-dimensional echocardiographic assessment. Ann Intern Med. 1987;106:663-670. FREE FULL TEXT 39. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness. J Am Coll Cardiol. 1986;8:57-65. ABSTRACT 40. Maron BJ, Gross BW, Stark SI. Images in cardiovascular medicine: extreme left ventricular hypertrophy. Circulation. 1995;92:2748. FREE FULL TEXT 41. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785. FREE FULL TEXT 42. Elliott PM, Gimeno Blanes JR, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-424. FULL TEXT | ISI | PUBMED 43. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA. 1996;276:199-204. FREE FULL TEXT 44. Maron BJ, Mathenge R, Casey SA, et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590-1595. FREE FULL TEXT 45. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998;339:364-369. FREE FULL TEXT 46. Spirito P, Maron BJ, Bonow RO, et al. Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy. J Am Coll Cardiol. 1986;8:537-544. ABSTRACT 47. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212-2218. FREE FULL TEXT 48. Pelliccia A, Maron BJ, Spataro A, et al. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324:295-301. ABSTRACT 49. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91:1596-1601. FREE FULL TEXT 50. Maron BJ. The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited. Ann Noninvasive Electrocardiol. 2001;6:277-279. FULL TEXT | ISI | PUBMED 51. Charron P, Dubourg O, Desnos M, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation. 1997;96:214-219. FREE FULL TEXT 52. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-614. ABSTRACT 53. Charron P, Dubourg O, Desnos M, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998;97:2230-2236. FREE FULL TEXT 54. Hagege AA, Dubourg O, Desnos M, et al. Familial hypertrophic cardiomyopathy. Eur Heart J. 1998;19:490-499. FREE FULL TEXT 55. Maron BJ, Nichols III PF, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy. Am J Cardiol. 1984;53:1087-1094. FULL TEXT | ISI | PUBMED 56. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1989;63:1258-1265. FULL TEXT | ISI | PUBMED 57. Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;9:1013-1017. ABSTRACT 58. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol. 1998;81:1339-1344. FULL TEXT | ISI | PUBMED 59. Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104:128-130. FREE FULL TEXT 60. Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001;104:1380-1384. FREE FULL TEXT 61. Obeid AI, Maron BJ. Apical hypertrophic cardiomyopathy developing at a relatively advanced age. Circulation. 2001;103:1605. FREE FULL TEXT 62. Shirani J, Maron BJ, Cannon III RO, et al. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol. 1993;72:434-440. FULL TEXT | ISI | PUBMED 63. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and age in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:820-823. ABSTRACT 64. Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy). Am J Cardiol. 1979;44:401-412. FULL TEXT | ISI | PUBMED 65. Klues HG, Roberts WC, Maron BJ. Morphologic determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87:1570-1579. FREE FULL TEXT 66. Maron BJ, Harding AM, Spirito P, et al. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in hypertrophic cardiomyopathy. Circulation. 1983;68:282-293. FREE FULL TEXT 67. Schwammenthal E, Block M, Schwartzkopff B, et al. Prediction of the site and severity of obstruction in hypertrophic cardiomyopathy by color flow mapping and continuous wave Doppler echocardiography. J Am Coll Cardiol. 1992;20:964-972. ABSTRACT 68. Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy. Am J Cardiol. 1981;48:258-262. FULL TEXT | ISI | PUBMED 69. Sherrid MV, Chu CK, Delia E, et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:816-825. ABSTRACT 70. Pollick C, Rakowski H, Wigle ED. Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and pressure gradient. Circulation. 1984;69:43-49. FREE FULL TEXT 71. Ferrans VJ, Morrow AG, Roberts WC. Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis. Circulation. 1972;45:769-792. FREE FULL TEXT 72. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. 1979;59:689-706. FREE FULL TEXT 73. St. John Sutton MG, Lie JT, Anderson KR, et al. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Br Heart J. 1980;44:433-443. FREE FULL TEXT 74. Varnava AM, Elliott PM, Mahon N, et al. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275-279. FULL TEXT | ISI | PUBMED 75. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation. 1981;63:882-894. FREE FULL TEXT 76. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545-557. ABSTRACT 77. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 1987;75:1130-1139. FREE FULL TEXT 78. Cannon III RO, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy. Circulation. 1985;71:234-243. FREE FULL TEXT 79. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998;97:230-233. FREE FULL TEXT 80. O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy. Circulation. 1987;76:1214-1223. FREE FULL TEXT 81. Cannon III RO, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:53-62. ABSTRACT 82. Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation. 1993;87:1580-1590. FREE FULL TEXT 83. Factor SM, Butany J, Sole MJ, et al. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;17:1343-1351. ABSTRACT 84. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of myocardial fibrosis in normal, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575-581. FREE FULL TEXT 85. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 1979;43:1086-1102. FULL TEXT | ISI | PUBMED 86. Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;17:879-886. ABSTRACT 87. Hanrath P, Mathey D, Montz R, et al. Myocardial thallium-201 imaging in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1981;2:177-185. FREE FULL TEXT 88. Suzuki Y, Kadota K, Nohara R, et al. Recognition of regional hypertrophy in hypertrophic cardiomyopathy using thallium-201 emission computed tomography. Am J Cardiol. 1984;53:1095-1102. FULL TEXT | ISI | PUBMED 89. Grover-McKay M, Schwaiger M, Krivokapich J, et al. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:317-324. ABSTRACT 90. Basso C, Thiene G, Corrado D, et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol. 2000;31:988-998. FULL TEXT | ISI | PUBMED 91. Takata J, Counihan PJ, Gane JN, et al. Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain. Am J Cardiol. 1993;72:211-217. FULL TEXT | ISI | PUBMED 92. Pasternac A, Noble J, Streulens Y, et al. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation. 1982;65:778-789. FREE FULL TEXT 93. Elliott PM, Kaski JC, Prasad K, et al. Chest pain during daily life in patients with hypertrophic cardiomyopathy. Eur Heart J. 1996;17:1056-1064. FREE FULL TEXT 94. Maron BJ, Wolfson JK, Roberts WC. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:785-790. FULL TEXT | ISI | PUBMED 95. Spirito P, Maron BJ, Chiarella F, et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy. Circulation. 1985;72:310-316. FREE FULL TEXT 96. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990;15:808-813. ABSTRACT 97. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36-44. FREE FULL TEXT 98. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373. FREE FULL TEXT 99. Silka MJ, Kron J, Dunnigan A, Dick II M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation. 1993;87:800-807. FREE FULL TEXT 100. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596-1601. FREE FULL TEXT 101. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med. 1988;318:1255-1257. ISI | PUBMED 102. Marian AJ, Yu QT, Workman R, et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342:1085-1086. FULL TEXT | ISI | PUBMED 103. Lechin M, Quiñones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation. 1995;92:1808-1812. FREE FULL TEXT 104. Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20:42-52. ABSTRACT 105. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:36-45. ABSTRACT 106. Skinner JR, Manzoor A, Hayes AM, et al. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart. 1997;77:229-233. FREE FULL TEXT 107. Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants. Circulation. 1982;65:7-17. FREE FULL TEXT 108. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child. 1984;59:971-975. FREE FULL TEXT 109. Fiddler GI, Tajik AJ, Weidman WH, et al. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol. 1978;42:793-799. FULL TEXT | ISI | PUBMED 110. Panza JA, Maris TJ, Maron BJ. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circulation. 1992;85:1398-1405. FREE FULL TEXT 111. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281:650-655. FREE FULL TEXT 112. Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Circulation. 1989;79:580-589. FREE FULL TEXT 113. Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol. 1990;16:821-826. ABSTRACT 114. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858-864. FREE FULL TEXT 115. Lewis JF, Maron BJ. Clinical and morphologic expression of hypertrophic cardiomyopathy in patients 65 years of age. Am J Cardiol. 1994;73:1105-1111. FULL TEXT | ISI | PUBMED 116. McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. Br Heart J. 1981;46:168-172. FREE FULL TEXT 117. Maron BJ, Savage DD, Wolfson JK, Epstein SE. The prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy. Am J Cardiol. 1981;48:252-257. FULL TEXT | ISI | PUBMED 118. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy. Circulation. 1982;65:1388-1394. FREE FULL TEXT 119. Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res. 1974;35:suppl II:179-195. 120. Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 1995;26:1529-1536. ABSTRACT 121. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 1993;72:970-972. FULL TEXT | ISI | PUBMED 122. Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320:749-755. ABSTRACT 123. Shapiro LM, Zezulka A. Hypertrophic cardiomyopathy: a common disease with a good prognosis: five year experience of a district general hospital. Br Heart J. 1983;50:530-533. FREE FULL TEXT 124. Cannan CR, Reeder GS, Bailey KR, Melton III LJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy. Circulation. 1995;92:2488-2495. FREE FULL TEXT 125. Spirito P, Rapezzi C, Autore C, et al. Prognosis in asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation. 1994;90:2743-2747. FREE FULL TEXT 126. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy. Am J Cardiol. 1993;72:939-943. FULL TEXT | ISI | PUBMED 127. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 1998;82:774-778. FULL TEXT | ISI | PUBMED 128. Niimura H, Patton KK, Maron BJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002;105:446-451. FREE FULL TEXT 129. Robinson KC, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990;15:1279-1285. ABSTRACT 130. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-2524. FREE FULL TEXT 131. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:301-307. FREE FULL TEXT 132. Krikler DM, Davies MJ, Rowland E, et al. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. Br Heart J. 1980;43:245-251. FREE FULL TEXT 133. Stafford WJ, Trohman RG, Bilsker M, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;7:701-704. ABSTRACT 134. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044-2051. FREE FULL TEXT 135. Sadoul N, Prasad K, Elliott PM, et al. Prospective diagnostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987-2991. FREE FULL TEXT 136. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol. 1989;13:1283-1288. ABSTRACT 137. Romeo F, Pelliccia F, Cristofani R, et al. Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant? Eur Heart J. 1990;11:233-240. FREE FULL TEXT 138. Yetman AT, McCrindle BW, MacDonald LC, et al. Myocardial bridging in children with hypertrophic cardiomyopathy. N Engl J Med. 1998;339:1201-1209. FREE FULL TEXT 139. Anan R, Shono H, Kisanuki A, et al. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. Circulation. 1998;98:391-397. FREE FULL TEXT 140. Watkins H. Sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:422-424. FREE FULL TEXT 141. Saumarez RC, Slade AK, Grace AA, et al. The significance of paced electrocardiogram fractionation in hypertrophic cardiomyopathy. Circulation. 1995;91:2762-2768. FREE FULL TEXT 142. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. Circulation. 1989;80:1259-1268. FREE FULL TEXT 143. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985;53:412-416. FREE FULL TEXT 144. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose -adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999;34:1813-1822. FREE FULL TEXT 145. Cecchi F, Olivotto I, Montereggi A, et al. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy. Heart. 1998;79:331-336. FREE FULL TEXT 146. Camm AJ, Nisam S. The utilization of the implantable defibrillator. Eur Heart J. 2000;21:1998-2004. FREE FULL TEXT 147. Maron BJ, Isner JM, McKenna WJ. Hypertrophic cardiomyopathy, myocarditis and other myopericardial disease, and mitral valve prolapse. In: 26th Bethesda Conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol. 1994;24:880-885. ISI | PUBMED 148. Maron BJ, Spirito P, Green KJ, et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:733-742. ABSTRACT 149. Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:787-796. FREE FULL TEXT 150. Briguori C, Betocchi S, Romano M, et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. Am J Cardiol. 1999;84:309-315. FULL TEXT | ISI | PUBMED 151. Lele SS, Thomson HL, Seo H, et al. Exercise capacity in hypertrophic cardiomyopathy. Circulation. 1995;92:2886-2894. FREE FULL TEXT 152. Frenneaux MP, Porter A, Caforio ALP, et al. Determinants of exercise capacity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:1521-1526. ABSTRACT 153. Chikamori T, Counihan PJ, Doi YL, et al. Mechanisms of exercise limitations in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19:507-512. ABSTRACT 154. Nihoyannopoulos P, Karatasakis G, Frenneaux M, et al. Diastolic function in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19:536-540. ABSTRACT 155. Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86:162-168. FULL TEXT | ISI | PUBMED 156. Lazzeroni E, Picano E, Morozzi L, et al. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Circulation. 1997;96:4268-4272. FREE FULL TEXT 157. Dilsizian V, Bonow RO, Epstein SE, et al. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:796-804. ABSTRACT 158. Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am J Cardiol. 1984;53:1614-1619. FULL TEXT | ISI | PUBMED 159. Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74:363-368. FULL TEXT | ISI | PUBMED 160. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21:1672-1679. ABSTRACT 161. Rosing DR, Condit JR, Maron BJ, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, III: effects of long-term administration. Am J Cardiol. 1981;48:545-553. FULL TEXT | ISI | PUBMED 162. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, II: effects on exercise capacity and symptomatic status. Circulation. 1979;60:1208-1213. FREE FULL TEXT 163. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437-441. FREE FULL TEXT 164. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1988;62:1085-1088. FULL TEXT | ISI | PUBMED 165. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997-999. ISI | PUBMED 166. Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 1998;97:41-47. FREE FULL TEXT 167. Hecht GM, Klues HG, Roberts WC, Maron BJ. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:489-497. ABSTRACT 168. Spirito P, Rapezzi C, Bellone P, et al. Infective endocarditis in hypertrophic cardiomyopathy. Circulation. 1999;99:2132-2137. FREE FULL TEXT 169. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosiss. Circulation. 1975;52:88-102. FREE FULL TEXT 170. Williams WG, Wigle ED, Rakowski H, et al. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation. 1987;76(5 Pt 2):V104-V108. 171. McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1996;94:467-471. FREE FULL TEXT 172. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586-594. FREE FULL TEXT 173. Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92(9 Suppl):II122-II127. 174. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Circulation. 1989;80(3 Pt I):I57-I64. 175. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation. 1988;78:487-495. FREE FULL TEXT 176. Cohn LH, Trehan H, Collin JJ Jr. Long-term follow-up of patients undergoing myotomy-myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:657-660. FULL TEXT | ISI | PUBMED 177. ten Berg JM, Suttorp MJ, Knaepen PJ, et al. Hypertrophic obstructive cardiomyopathy: initial results and long-term follow-up after Morrow septal myectomy. Circulation. 1994;90:1781-1785. FREE FULL TEXT 178. Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 1995;110:195-208. FREE FULL TEXT 179. Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg. 1996;112:1589-1599. FREE FULL TEXT 180. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998;98:2505-2508. FREE FULL TEXT 181. Ommen SR, Nishimura RA, Squires RW, et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999;34:191-196. FREE FULL TEXT 182. Brunner-La Schonbeck MH, Rocca HP, Vogt PR, et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg. 1998;65:1207-1214. FREE FULL TEXT 183. Yu EHC, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36:2219-2225. FREE FULL TEXT 184. Schulte HD, Bircks WH, Loesse B, et al. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. J Thorac Cardiovasc Surg. 1993;106:709-717. ABSTRACT 185. Petrone RK, Klues HG, Panza JA, et al. Significance of the occurrence of mitral valve prolapse in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20:55-61. ABSTRACT 186. Cannon III RO, McIntosh CL, Schenke WH, et al. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation. 1989;79:766-775. FREE FULL TEXT 187. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97:461-466. FREE FULL TEXT 188. Klues HG, Leuner C, Kuhn H. Hypertrophic obstructive cardiomyopathy: no increase of the gradient during exercise. J Am Coll Cardiol. 1991;19:527-533. 189. Gilligan DM, Chan WL, Ang EL, Oakley CM. Effects of a meal on hemodynamic function at rest and during exercise in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;18:429-436. ABSTRACT 190. Murgo J, Alter BR, Dorethy JF, et al. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. J Clin Invest. 1980;66:1369-1382. ISI | PUBMED 191. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet. 2000;355:425-426. ISI | PUBMED 192. Bryce M, Spielman SR, Greenspan AM, Kotler MN. Evolving indications for permanent pacemakers. Ann Intern Med. 2001;134:1130-1141. FREE FULL TEXT 193. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Circulation. 1994;90:2731-2742. FREE FULL TEXT 194. Slade AKB, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75:44-49. FREE FULL TEXT 195. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation. 1999;99:2927-2933. FREE FULL TEXT 196. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 1997;29:435-441. ABSTRACT 197. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1997;18:1249-1256. FREE FULL TEXT 198. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:903-907. FULL TEXT | ISI | PUBMED 199. Gadler F, Linde C, Daubert C, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic cardiomyopathy: data from 1 year of follow-up. Eur Heart J. 1999;20:1044-1050. FREE FULL TEXT 200. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1997;95:2075-2081. FREE FULL TEXT 201. Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Heart. 2000;83:326-331. FREE FULL TEXT 202. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750-1755. FREE FULL TEXT 203. Geitzen FH, Leuner ChJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J. 1999;20:1342-1354. FREE FULL TEXT 204. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492-1496. FREE FULL TEXT 205. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2001;38:1701-1706. FREE FULL TEXT 206. Wigle ED, Schwartz L, Woo A, Rakowski H. To ablate or operate? that is the question. J Am Coll Cardiol. 2001;15:1707-1710. 207. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38:1994-2000. FREE FULL TEXT

Clinical Cardiology Section Editor: Michael S. Lauer, MD, Contributing Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

March 13, 2002
JAMA. 2002;287(10):1333-1334.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiovascular Health, Part 1: Preparticipation Cardiovascular Screening
Gupta et al.
Sports Health: A Multidisciplinary Approach 2009;1:500-507.
ABSTRACT | FULL TEXT  

Transgenerational genetic effects on phenotypic variation and disease risk
Nadeau
Hum Mol Genet 2009;18:R202-R210.
ABSTRACT | FULL TEXT  

Unusual cause of stroke in hypertrophic cardiomyopathy
Basavarajaiah et al.
Heart 2009;95:1592-1592.
FULL TEXT  

Regional abnormalities of myocardial deformation in patients with hypertrophic cardiomyopathy: correlations with delayed enhancement in cardiac magnetic resonance
Ghio et al.
Eur J Heart Fail 2009;11:952-957.
ABSTRACT | FULL TEXT  

Identification of Unexpected Nonatherosclerotic Cardiovascular Disease With Coronary CT Angiography
Knickelbine et al.
J Am Coll Cardiol Img 2009;2:1085-1092.
ABSTRACT | FULL TEXT  

Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening
Maron
Br. J. Sports. Med. 2009;43:649-656.
ABSTRACT | FULL TEXT  

Electrocardiographic screening in athletes: the time is now for universal screening
Papadakis and Sharma
Br. J. Sports. Med. 2009;43:663-668.
ABSTRACT | FULL TEXT  

Return to play? Practical considerations for young athletes with cardiovascular disease
Anderson and Vetter
Br. J. Sports. Med. 2009;43:690-695.
ABSTRACT | FULL TEXT  

The case for myocardial ischemia in hypertrophic cardiomyopathy.
Maron et al.
J Am Coll Cardiol 2009;54:866-875.
ABSTRACT | FULL TEXT  

Solution Structure of Human Cardiac Troponin C in Complex with the Green Tea Polyphenol, (-)-Epigallocatechin 3-Gallate
Robertson et al.
J. Biol. Chem. 2009;284:23012-23023.
ABSTRACT | FULL TEXT  

Ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy
Carrier et al.
Cardiovasc Res 2009;0:cvp247v2-cvp247.
ABSTRACT | FULL TEXT  

The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.
Maron et al.
J Am Coll Cardiol 2009;54:191-200.
ABSTRACT | FULL TEXT  

Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.
Bos et al.
J Am Coll Cardiol 2009;54:201-211.
ABSTRACT | FULL TEXT  

Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance.
Maron et al.
J Am Coll Cardiol 2009;54:220-228.
ABSTRACT | FULL TEXT  

Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study.
Sorajja et al.
J Am Coll Cardiol 2009;54:234-241.
ABSTRACT | FULL TEXT  

A Functional and Structural Study of Troponin C Mutations Related to Hypertrophic Cardiomyopathy
Pinto et al.
J. Biol. Chem. 2009;284:19090-19100.
ABSTRACT | FULL TEXT  

Prevalence and significance of T-wave inversions in predominantly Caucasian adolescent athletes
Papadakis et al.
Eur Heart J 2009;30:1728-1735.
ABSTRACT | FULL TEXT  

Expression Patterns of Cardiac Myofilament Proteins: Genomic and Protein Analysis of Surgical Myectomy Tissue From Patients With Obstructive Hypertrophic Cardiomyopathy
Theis et al.
Circ Heart Fail 2009;2:325-333.
ABSTRACT | FULL TEXT  

Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil
Olivotto et al.
Eur Heart J 2009;30:1549-1550.
FULL TEXT  

Overlapping Phenotypes: Left Ventricular Noncompaction and Hypertrophic Cardiomyopathy
Kelley-Hedgepeth et al.
Circulation 2009;119:e588-e589.
FULL TEXT  

Inducible Malignant Ventricular Tachyarrhythmia in a Patient With Genotyped Hypertrophic Cardiomyopathy in Absence of Left Ventricular Hypertrophy or Enlargement
Ariyarajah et al.
Circulation 2009;119:e543-e544.
FULL TEXT  

ST-segment depression as a risk factor in hypertrophic cardiomyopathy
Haghjoo et al.
Europace 2009;11:643-649.
ABSTRACT | FULL TEXT  

Left ventricular hypertrophy in athletes
Rawlins et al.
Eur J Echocardiogr 2009;10:350-356.
ABSTRACT | FULL TEXT  

Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy
Spirito et al.
Circulation 2009;119:1703-1710.
ABSTRACT | FULL TEXT  

Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity?
Kelly and Semsarian
Circ Cardiovasc Genet 2009;2:182-190.
FULL TEXT  

Advances in the prevention of sudden cardiac death in the young
Shephard and Semsarian
Ther Adv Cardiovasc Dis 2009;3:145-155.
ABSTRACT  

Immediate improvement in coronary flow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
Jaber et al.
Heart 2009;95:564-569.
ABSTRACT | FULL TEXT  

Influence of the pattern of hypertrophy on left ventricular twist in hypertrophic cardiomyopathy
van Dalen et al.
Heart 2009;95:657-661.
ABSTRACT | FULL TEXT  

Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice
Abraham et al.
Cardiovasc Res 2009;82:84-92.
ABSTRACT | FULL TEXT  

Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms
Lombardi et al.
Circulation 2009;119:1398-1407.
ABSTRACT | FULL TEXT  

Recent advances in diagnosis and management of hypertrophic cardiomyopathy
Siswanto and Aryani
Heart Asia 2009;2009:1-4.
ABSTRACT | FULL TEXT  

Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice
Kerrick et al.
FASEB J. 2009;23:855-865.
ABSTRACT | FULL TEXT  

Hypertrophic cardiomyopathy: current understanding and treatment objectives
Soor et al.
J. Clin. Pathol. 2009;62:226-235.
ABSTRACT | FULL TEXT  

AJR Teaching File: Asymptomatic Man with Giant Negative T Waves on ECG
Attili et al.
Am. J. Roentgenol. 2009;192:S57-S61.
FULL TEXT  

How should hypertrophic cardiomyopathy be classified?: What's in a Name? Dilemmas in Nomenclature Characterizing Hypertrophic Cardiomyopathy and Left Ventricular Hypertrophy
Maron et al.
Circ Cardiovasc Genet 2009;2:81-86.
FULL TEXT  

Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging
Esposito et al.
Heart 2009;95:228-233.
ABSTRACT | FULL TEXT  

Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
Cambronero et al.
Eur Heart J 2009;0:ehn538v1-13.
ABSTRACT | FULL TEXT  

Hypertrophic cardiomyopathy without hypertrophy: an emerging pre-clinical subgroup composed of genetically affected family members.
Maron and Ho
J Am Coll Cardiol Img 2009;2:65-68.
FULL TEXT  

The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic Cardiomyopathy: A Pilot, Randomized Study
Penicka et al.
J. Mol. Diagn. 2009;11:35-41.
ABSTRACT | FULL TEXT  

A Pattern-based Approach to Assessment of Delayed Enhancement in Nonischemic Cardiomyopathy at MR Imaging1
Cummings et al.
RadioGraphics 2009;29:89-103.
ABSTRACT | FULL TEXT  

CHAPTER 18 Myocardial Disease
Hess et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

CHAPTER 26 Syncope
Brignole et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

Standards for LVH in Elite Athletes
Bernhardt
AAP Grand Rounds 2008;20:65-65.
FULL TEXT  

Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death After Alcohol Septal Ablation of Hypertrophic Cardiomyopathy
Cuoco et al.
J Am Coll Cardiol 2008;52:1718-1723.
ABSTRACT | FULL TEXT  

Resection-Plication-Release for Hypertrophic Cardiomyopathy: Clinical and Echocardiographic Follow-Up
Balaram et al.
Ann. Thorac. Surg. 2008;86:1539-1545.
ABSTRACT | FULL TEXT  

Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies.
Afonso et al.
J Am Coll Cardiol Img 2008;1:787-800.
ABSTRACT | FULL TEXT  

Myocardial deformation abnormalities in paediatric hypertrophic cardiomyopathy: are all aetiologies identical?
Ganame et al.
Eur J Echocardiogr 2008;9:784-790.
ABSTRACT | FULL TEXT  

Acceleration of Crossbridge Kinetics by Protein Kinase A Phosphorylation of Cardiac Myosin Binding Protein C Modulates Cardiac Function
Tong et al.
Circ. Res. 2008;103:974-982.
ABSTRACT | FULL TEXT  

Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy
Maron et al.
Circulation 2008;118:1541-1549.
ABSTRACT | FULL TEXT  

Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy: An Invasive Hemodynamic Study
Sorajja et al.
J Am Coll Cardiol Intv 2008;1:552-560.
ABSTRACT | FULL TEXT  

Bringing the obstruction back into hypertrophic cardiomyopathy
Murphy
Heart 2008;94:1249-1250.
FULL TEXT  

Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes
Sakata et al.
Heart 2008;94:1282-1287.
ABSTRACT | FULL TEXT  

B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy
Kaski et al.
Heart 2008;94:1307-1311.
ABSTRACT | FULL TEXT  

Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy
Steendijk et al.
Heart 2008;94:1318-1322.
ABSTRACT | FULL TEXT  

Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish
Zahka et al.
Heart 2008;94:1326-1330.
ABSTRACT | FULL TEXT  

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future
Ommen et al.
Heart 2008;94:1276-1281.
FULL TEXT  

Preparticipation screening for cardiovascular abnormalities in young competitive athletes
Papadakis et al.
BMJ 2008;337:a1596-a1596.
FULL TEXT  

Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy
Maron et al.
Circ Heart Fail 2008;1:184-191.
ABSTRACT | FULL TEXT  

Left ventricular outflow tract obstruction in the presence of asymmetric septal hypertrophy and accessory mitral valve tissue treated with alcohol septal ablation
Kim et al.
Eur J Echocardiogr 2008;9:720-724.
ABSTRACT | FULL TEXT  

Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy
Olivotto et al.
J Am Coll Cardiol 2008;52:559-566.
ABSTRACT | FULL TEXT  

Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
Sorajja et al.
Circulation 2008;118:131-139.
ABSTRACT | FULL TEXT  

The Risk in Exercise Training
Foster et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:279-284.
ABSTRACT  

Impact of Percutaneous Transluminal Septal Myocardial Ablation on Refractory Paroxysmal Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy
Hosokawa et al.
ANGIOLOGY 2008;59:329-334.
ABSTRACT  

Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy
Saumarez et al.
Eur Heart J 2008;29:1653-1661.
ABSTRACT | FULL TEXT  

Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy
Sotgia et al.
JNM 2008;49:1090-1096.
ABSTRACT | FULL TEXT  

A novel mouse model of X-linked cardiac hypertrophy
Leatherbury et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H2701-H2711.
ABSTRACT | FULL TEXT  

The 2006 American Heart Association Classification of Cardiomyopathies Is the Gold Standard
Maron
Circ Heart Fail 2008;1:72-76.
FULL TEXT  

Oral Disopyramide for the Acute Treatment of Severe Outflow Obstruction in Hypertrophic Cardiomyopathy in the ICU Setting
Sirak and Sherrid
Chest 2008;133:1243-1246.
ABSTRACT | FULL TEXT  

Disease-Modifying Mutations in Familial Hypertrophic Cardiomyopathy: Complexity From Simplicity
Hilfiker-Kleiner and Knoll
Circulation 2008;117:1775-1777.
FULL TEXT  

Severe Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial Hypertrophic Cardiomyopathy
Tsoutsman et al.
Circulation 2008;117:1820-1831.
ABSTRACT | FULL TEXT  

Medical Conditions Affecting Sports Participation
Rice and and the Council on Sports Medicine and Fitness
Pediatrics 2008;121:841-848.
ABSTRACT | FULL TEXT  

Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy
Bayrak et al.
Eur J Echocardiogr 2008;9:278-283.
ABSTRACT | FULL TEXT  

Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils
Iorga et al.
Cardiovasc Res 2008;77:676-686.
ABSTRACT | FULL TEXT  

Pathology of Cardiac Surgery
Padera and Schoen
Card Surg Adult 2008;3:111-178.
FULL TEXT  

Regional myocardial deformation in children with hypertrophic cardiomyopathy: morphological and clinical correlations
Ganame et al.
Eur Heart J 2007;28:2886-2894.
ABSTRACT | FULL TEXT  

Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients
Szczesna-Cordary et al.
FASEB J. 2007;21:3974-3985.
ABSTRACT | FULL TEXT  

Septal Myectomy After Previous Septal Artery Ablation in Hypertrophic Cardiomyopathy
ElBardissi et al.
Mayo Clin Proc. 2007;82:1516-1522.
ABSTRACT | FULL TEXT  

Electrocardiograms Should Be Included in Preparticipation Screening of Athletes
Myerburg and Vetter
Circulation 2007;116:2616-2626.
FULL TEXT  

Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy
McLeod et al.
Eur Heart J 2007;28:2583-2588.
ABSTRACT | FULL TEXT  

Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy
Daw et al.
Hum Mol Genet 2007;16:2463-2471.
ABSTRACT | FULL TEXT  

Gray zone problem in athletes
Kasikcioglu
Eur Heart J 2007;28:2415-2416.
FULL TEXT  

Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Maron et al.
JAMA 2007;298:405-412.
ABSTRACT | FULL TEXT  

Hypertrophic Cardiomyopathy, Sudden Death, and Implantable Cardiac Defibrillators: How Low the Bar?
Nishimura and Ommen
JAMA 2007;298:452-454.
FULL TEXT